nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.11.2006 | Original Paper

Combined profile of the tandem repeats CAG, TA and CA of the androgen and estrogen receptor genes in breast cancer

verfasst von: Andrei Anghel, Marius Raica, Catalin Marian, Sorin Ursoniu, Oana Mitrasca

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 11/2006

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Case–control studies have reported inconsistent results concerning the association between polymorphisms in the androgen and estrogen receptor (ER) genes and breast cancer. While several studies investigated the association between the androgen receptor (AR) gene, CAG repeat and breast cancer, for the CA and TA repeats in the ER genes there are considerably fewer studies (one for CA and none for TA).

Methods

We have investigated the potential link between three tandem repeats (CAG, TA, and CA) in the AR, ERs α and β genes, respectively, and breast cancer. DNA was isolated from 153 invasive breast tumors and 318 controls, and the three tandem repeats were sized by polyacrylamide electrophoresis. Number of repeats in each allele and the total repeats of both alleles were taken as variables for classification into dichotomous groups using the median of each variable in the control group as cut-off point. Relationship between polymorphic tandem repeats and breast cancer was assessed by multivariate logistic regression models.

Results

Three variables combined, longer CAGsum (≥28), shorter TA (<23) and CA (<23) repeats could constitute a possible genetic profile associated with breast cancer.

Conclusions

Our results confirm previous reports regarding an association between longer CAG repeats and breast cancer. In addition to that, we found that the combination of long CAG, short TA and CA repeats are strongly associated with breast cancer.

Antoniou AC, Pharoah PD, McMullan G, Day NE, Ponder BA, Easton D (2001) Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. Genet Epidemiol 21:1–18PubMedCrossRef

Bayer-Garner IB, Smoller B (2000) Androgen receptors: a marker to increase sensitivity for identifying breast cancer in skin metastasis of unknown primary site. Mod Pathol 13:119–122PubMedCrossRef

Beato M, Herrlich P, Schutz G (1995) Steroid hormone receptors: many actors in search of a plot. Cell 83:851–857PubMedCrossRef

Becherini L, Gennari L, Masi L (2000) Evidence of a linkage disequilibrium between polymorphisms in the human estrogen receptor alpha gene and their relationship to bone mass variation in postmenopausal Italian women. Hum Mol Genet 9:2043–2050PubMedCrossRef

Berrino F, Muti P, Micheli A, Bolelli G, Krogh V, Sciajno R, Pisani P, Panico S, Secreto G (1996) Serum sex hormone levels after menopause and subsequent breast cancer. J Natl Cancer Inst 88:291–296PubMedCrossRef

Bryan RM, Mercer RJ, Bennett RC, Rennie GC, Lie TH, Morgan FJ (1984) Androgen receptors in breast cancer. Cancer 54:2436–2440PubMedCrossRef

Brys M, Wojcik M, Romanowicz-Makowska H, Krajewska WM (2002) Androgen receptor status in female breast cancer: RT-PCR and Western blot studies. J Cancer Res Clin Oncol 128:85–90PubMedCrossRef

Cauley JA, Lucas FL, Kuller LH, Stone K, Browner W, Cummings SR (1999) Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer: study of Osteoporotic Fractures Research Group. Ann Intern Med 130:270–277PubMed

Chamberlain NL, Driver ED, Miesfeld RL (1994) The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 22:3181–3186PubMedCrossRef

Comings DE (1998) Polygenic inheritance and micro/minisatellites. Mol Psychiatry 3:21–31PubMedCrossRef

Comings DE, Muhleman D, Johnson P, MacMurray JP (1999) Potential role of the estrogen receptor gene (ESR1) in anxiety. Mol Psychiatry 4:374–377PubMedCrossRef

Dagan E, Friedman E, Paperna T, Carmi N, Gershoni-Baruch R (2002) Androgen receptor CAG repeat length in Jewish Israeli women who are BRCA1/2 mutation carriers: association with breast/ovarian cancer phenotype. Eur J Hum Genet 10:724–728PubMedCrossRef

Dorgan JF, Longcope C, Stephenson HE Jr, Falk RT, Miller R, Franz C, Kahle L, Campbell WS, Tangrea JA, Schatzkin A (1996) Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk. Cancer Epidemiol Biomarkers Prev 5:533–539PubMed

Elhaji YA, Gottlieb B, Lumbroso R, Beitel LK, Foulkes WD, Pinsky L, Trifiro MA (2001) The polymorphic CAG repeat of the androgen receptor gene: a potential role in breast cancer in women over 40. Breast Cancer Res Treat 70:109–116PubMedCrossRef

Forsti A, Zhao C, Israelsson E, Dahlman-Wright K, Gustafsson JA, Hemminki K (2003) Polymorphisms in the estrogen receptor beta gene and risk of breast cancer: no association. Breast Cancer Res Treat 79:409–413PubMedCrossRef

Garland CF, Friedlander NJ, Barrett-Connor E, Khaw KT (1992) Sex hormones and postmenopausal breast cancer: a prospective study in an adult community. Am J Epidemiol 135:1220–1230PubMed

Georgiou I, Syrrou M, Bouba I (1999) Association of estrogen receptor gene polymorphisms with endometriosis. Fertil Steril 72:164–166PubMedCrossRef

Giguere Y, Dewailly E, Brisson J, Ayotte P, Laflamme N, Demers A, Forest VI, Dodin S, Robert J, Rousseau F (2001) Short polyglutamine tracts in the androgen receptor are protective against breast cancer in the general population. Cancer Res 61:5869–5874PubMed

Given HF, Radbourne R, Oag H, Merritt S, Barclay E, Hanby AM, Lamlum H, McGrath J, Curran C, Tomlinson IP (2000) The androgen receptor exon 1 trinucleotide repeat does not act as a modifier of the age of presentation in breast cancer. Eur J Cancer 36:533–534PubMedCrossRef

Hackenberg R, Hofmann J, Holzel F, Schulz KD (1988) Stimulatory effects of androgen and antiandrogen on the in vitro proliferation of human mammary carcinoma cells. J Cancer Res Clin Oncol 114:593–601PubMedCrossRef

Haiman CA, Brown M, Hankinson SE, Spiegelman D, Colditz GA, Willett WC, Kantoff PW, Hunter DJ (2002) The androgen receptor CAG repeat polymorphism and risk of breast cancer in the Nurses’ Health Study. Cancer Res 62:1045–1049PubMed

Hall RE, Aspinall JO, Horsfall DJ, Birrell SN, Bentel JM, Sutherland RL, Tilley WD (1996) Expression of the androgen receptor and an androgen-responsive protein, apolipoprotein D, in human breast cancer. Br J Cancer 74:1175–1180PubMed

Hankinson SE, Willett WC, Manson JE, Colditz GA, Hunter DJ, Spiegelman D, Barbieri RL, Speizer FE (1998) Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 90:1292–1299PubMedCrossRef

Irvine RA, Ma H, Yu MC, Ross RK, Stallcup MR, Coetzee GA (2000) Inhibition of p 160-mediated coactivation with increasing androgen receptor polyglutamine length. Hum Mol Genet 9:267–274PubMedCrossRef

Jensen EV, Jacobson HI (1962) Basic guides to the mechanism of estrogen action. Recent Prog Horm Res 18:387–414

Jenster J, van der Korput HA, Trapman J, Brinkmann AO (1995) Identification of two transcription activation units in the N-terminal domain of the human androgen receptor. J Biol Chem 270:7341–7346PubMedCrossRef

Kadouri L, Easton DF, Edwards S, Hubert A, Kote-Jarai Z, Glaser B, Durocher F, Abeliovich D, Peretz T, Eeles RA (2001) CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers. Br J Cancer 85:36–40PubMedCrossRef

Kuenen-Boumeester V, van der Kwast TH, van Putten WL, Claasen C, van Ooijen B, Henzen-Logmans SC (1992) Immunohistochemical determination of androgen receptors in relation to estrogen and progesterone receptors in female breast cancer. Int J Cancer 52:581–584PubMedCrossRef

Kunnas TA, Laippala P, Penttila A, Lehtimaki T, Karhunen PJ (2000) Association of polymorphism of human alpha oestrogen receptor gene with coronary artery disease in men: a necropsy study. Br Med J 321:273–274CrossRef

Langdahl BL, Lokke E, Carstens M, Stenkjaer LL, Eriksen EF (2000) A TA repeat polymorphism in the estrogen receptor gene is associated with osteoporotic fractures but polymorphisms in the first exon and intron are not. J Bone Miner Res 15:2222–2230PubMedCrossRef

Lea OA, Kvinnsland S, Thorsen T (1989) Improved measurement of androgen receptors in human breast cancer. Cancer Res 49:7162–7167PubMed

Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K (2000) Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark and Finland. N Engl J Med 343:78–85PubMedCrossRef

Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM (1995) The nuclear receptor superfamily: the second decade. Cell 83:835–839PubMedCrossRef

Marugo M, Bernasconi D, Miglietta L, Fazzuoli L, Ravera F, Cassulo S, Giordano G (1992) Effects of dihydrotestosterone and hydroxyflutamide on androgen receptors in cultured human breast cancer cells (EVSA-T). J Steroid Biochem Mol Biol 42:547–554PubMedCrossRef

Menin C, Banna GL, De Salvo G, Lazzarotto V, De Nicolo A, Agata S, Montagna M, Sordi G, Nicoletto O, Chieco-Bianchi L, D’Andrea E (2001) Lack of association between androgen receptor CAG polymorphism and familial breast/ovarian cancer. Cancer Lett 168:31–36PubMedCrossRef

Ogawa S, Hosoi T, Shiraki M (2000) Association of estrogen receptor b gene polymorphism with bone mineral density. Biochem Biophys Res Commun 269:537–541PubMedCrossRef

Ortmann J, Prifti S, Bohlmann MK, Rehberger-Schneider S, Strowitzki T, Rabe T (2002) Testosterone and 5 alpha-dihydrotestosterone inhibit in vitro growth of human breast cancer cell lines. Gynecol Endocrinol 16:113–120PubMedCrossRef

Poulin R, Baker D, Labrie F (1988) Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line. Breast Cancer Res Treat 12:213–225PubMedCrossRef

Rebbeck TR, Kantoff PW, Krithivas K, Neuhausen S, Blackwood MA, Godwin AK, Daly MB, Narod SA, Garber JE, Lynch HT, Weber BL, Brown M (1999) Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am J Hum Genet 64:1371–1377PubMedCrossRef

Rosai J (2004) Rosai and Ackerman’s surgical pathology. C.V. Mosby, St Louis, pp. 2871–2873

del Senno L, Aguiari GL, Piva R (1992) Dinucleotide repeat polymorphism in the human estrogen receptor (ESR) gene. Hum Mol Genet 1:534CrossRef

Sommer S, Fuqua SA (2001) Estrogen receptor and breast cancer. Semin Cancer Biol 11:339–352PubMedCrossRef

Soreide JA, Lea OA, Varhaug JE, Skarstein A, Kvinnsland S (1992) Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment. Eur J Surg Oncol 18:112–118PubMed

Spurdle AB, Dite GS, Chen X, Mayne CJ, Southey MC, Batten LE, Chy H, Trute L, McCredie MR, Giles GG, Armes J, Venter DJ, Hopper JL, Chenevix-Trench G (1999) Androgen receptor exon 1 CAG repeat length and breast cancer in women before age forty years. J Natl Cancer Inst 91:961–966PubMedCrossRef

Syrrou M, Georgiou I, Patsalis PC, Bouba I, Adonakis G, Pagoulatos GN (1999) Fragile X premutations and (TA)n estrogen receptor polymorphism in women with ovarian dysfunction. Am J Med Genet 84:306–308PubMedCrossRef

Thomas HV, Key TJ, Allen DS, Moore JW, Dowsett M, Fentiman IS, Wang DY (1997) A prospective study of endogenous serum hormone concentrations and breast cancer risk in postmenopausal women on the island of Guernsey. Br J Cancer 76:401–405PubMed

Tsukamoto K, Inoue S, Hosoi T, Orimo H, Emi M (1998) Isolation and radiation hybrid mapping of dinucleotide repeat polymorphism at the human estrogen receptor beta locus. J Hum Genet 43:73–74PubMedCrossRef

Westberg L, Baghaei F, Rosmond R, Hellstrand M, Landen M, Jansson M, Holm G, Bjorntrop P, Eriksson E (2001) Polymorphisms of the androgen receptor gene and the estrogen receptor β gene are associated with androgen levels in women. J Clin Endocrinol Metab 86(6):2562–2566PubMedCrossRef

White R, Parker MG (1998) Molecular mechanisms of steroid hormone action. Endocr Relat Cancer 5:1–14CrossRef

Wysowski DK, Comstock GW, Helsing KJ, Lau HL (1987) Sex hormone levels in serum in relation to the development of breast cancer. Am J Epidemiol 125:791–799PubMed

Yu H, Bharaj B, Vassilikos EJ, Giai M, Diamandis EP (2000) Shorter CAG repeat length in the androgen receptor gene is associated with more aggressive forms of breast cancer. Breast Cancer Res Treat 59:153–161PubMedCrossRef

Zava DT, McGuire WL (1977) Estrogen receptors in androgen-induced breast tumor regression. Cancer Res 37:1608–1610PubMed

Zeleniuch-Jacquotte A, Bruning PF, Bonfrer JM, Koenig KL, Shore RE, Kim MY, Pasternack BS, Toniolo P (1997) Relation of serum levels of testosterone and dehydroepiandrosterone sulfate to risk of breast cancer in postmenopausal women. Am J Epidemiol 145:1030–1038PubMed

Titel: Combined profile of the tandem repeats CAG, TA and CA of the androgen and estrogen receptor genes in breast cancer
verfasst von: Andrei Anghel
Marius Raica
Catalin Marian
Sorin Ursoniu
Oana Mitrasca
Publikationsdatum: 01.11.2006
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 11/2006
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-006-0121-9

Neu im Fachgebiet Onkologie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Combined profile of the tandem repeats CAG, TA and CA of the androgen and estrogen receptor genes in breast cancer

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2006

Impact of biomarkers on disease survival and progression in patients treated with octreotide for advanced hepatocellular carcinoma

The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma

Aberrant promoter hypermethylation of p16 and MGMT genes in oral squamous cell carcinomas and the surrounding normal mucosa

Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy

The membrane-cytoskeleton organizer ezrin is necessary for hepatocellular carcinoma cell growth and invasiveness

Elevation of soluble interleukin-2 receptor in patients with non-small cell lung cancer treated with gefitinib

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie